Maintenance Immunotherapy After Chemotherapy in Bladder Cancer — What It Is and Who Qualifies

It is checkpoint inhibitor treatment started after first-line platinum-based chemotherapy, in patients whose advanced urothelial cancer has not progressed. It applies to advanced or metastatic disease only, so most bladder cancer patients are not candidates. It is not extra chemotherapy. It is not given because treatment has failed.

Who this does not apply to, stated first. Non-muscle-invasive bladder cancer treated with instillations into the bladder is a different pathway. Muscle-invasive disease treated with surgery or chemoradiation is a different pathway. Anyone whose cancer grew during chemotherapy is not a maintenance candidate either, because maintenance is defined by the absence of progression. Ruling these groups out is not a technicality — it is most of the people who search this phrase.

What “maintenance” means here. It is sometimes called switch maintenance, because the class of treatment changes while the goal stays the same: holding disease that is currently controlled. Platinum-based chemotherapy is given for a fixed number of cycles and then stopped, because prolonged platinum treatment is hard on the kidneys, the nerves and the blood counts. Stopping leaves a gap. Maintenance fills that gap with a treatment class that can generally be continued for far longer.

Why this is described as having replaced an older standard. For years the plan after first-line chemotherapy was observation: scans every couple of months, and a new line of treatment only once the cancer grew. NCCN and ESMO now list maintenance checkpoint inhibitor treatment as a preferred option for patients whose disease did not progress on chemotherapy. Patients are still sometimes put on observation without the alternative being raised at all.

Nothing on this page decides whether maintenance applies. That rests on the histology report, the scan done after chemotherapy, kidney and organ function, and immune history, read together by a medical oncologist.

A narrow group. Locally advanced or metastatic urothelial carcinoma, four to six cycles of first-line platinum-based chemotherapy completed, and a scan afterwards showing the disease has not progressed. Treatment usually begins a few weeks after the last chemotherapy cycle. Autoimmune disease, a transplant and high-dose steroids can close the door.

• The cancer has to be urothelial and advanced — maintenance is for locally advanced or metastatic urothelial carcinoma, which includes tumours arising in the bladder and in the upper urinary tract. Disease that is still surgically curable follows a different pathway entirely.
• First-line platinum chemotherapy has to have been completed — generally four to six cycles of a platinum-based combination. Chemotherapy stopped early because of toxicity, or a shorter course, becomes a case-by-case discussion rather than an automatic yes.
• The scan afterwards has to show no progression — complete response, partial response and stable disease all qualify. Measurable growth or new sites of disease on the post-chemotherapy scan means the situation has moved past this option, and a different line of treatment is considered instead.
• The gap after chemotherapy is short — maintenance is generally started a few weeks after the last cycle, not months later.
• Organ function and blood counts are checked first — kidney function especially, because platinum chemotherapy has just been given, because an obstructed ureter is common in this cancer, and because some patients have had a kidney or ureter removed.
• Immune history can rule it out — active autoimmune disease, a solid organ transplant, or ongoing high-dose steroids make checkpoint inhibitor treatment unsuitable or higher-risk, because it works by loosening restraints on the immune system rather than targeting the tumour directly.

There is no fixed number of cycles. Maintenance continues while the cancer stays controlled and the treatment is tolerated, with infusions every two to four weeks depending on the schedule chosen. It stops on progression, on a serious immune-related side effect, or by a considered decision between patient and treating team.

Why open-ended treatment is harder than it sounds. Chemotherapy has a countable end. Six cycles is six cycles, and families organise leave, money and travel around that number. Maintenance replaces “four more cycles” with “we will keep going while it works”, and that is a genuinely different thing to live with. It is fair to ask at every review what the current plan is, what would end it, and what the next review will look at.

What actually brings it to an end. Three things, and they should be named out loud before the first infusion. Progression on imaging. An immune-related side effect — inflammation of the bowel, lungs, liver, thyroid, kidneys or other organs — serious enough that continuing is unsafe. Or a decision that the burden of travelling for infusions and tests outweighs what the treatment is doing, which is a legitimate reason and not a failure of nerve.

Can it be stopped after a long period of control? This is asked constantly by patients doing well, and the honest answer is that the evidence is immature. There is no settled duration after which stopping is known to be safe, and guidance does not give one. Some teams discuss a planned pause in patients with a long, stable response. If that is considered, it should be a documented decision with a surveillance schedule attached to it, not a quiet drift out of follow-up.

What the schedule looks like in practice. Infusions are given as day care at CION centres, so there is no hospital admission for a routine cycle. Blood tests are done before each cycle. Imaging is repeated at fixed intervals, commonly every couple of months at first and less often once the picture is stable; response-assessment and restaging scans are coordinated at partner imaging centres rather than performed in-house.

By protocol, not by symptoms. Creatinine, eGFR and urine protein are recorded at baseline and repeated before every cycle, alongside thyroid, liver function and blood counts. This matters more than usual in urothelial cancer, because kidney function is often already reduced before maintenance begins.

• Baseline before the first maintenance infusion — creatinine, eGFR and urine protein are recorded as the reference every later result is compared against. Platinum chemotherapy has only just finished and may itself have moved these numbers, so the baseline is taken fresh rather than carried over.
• Before every cycle after that — the same panel is repeated on a fixed schedule. A rising creatinine is a trigger for review by the treating team, not automatically a reason to stop treatment.
• Obstruction is checked, not assumed — a urothelial tumour can block drainage from a kidney. Upper-tract imaging and kidney bloods are read together, so a falling eGFR is attributed to the right cause before the treatment plan is changed.
• Immune-related nephritis is a recognised, uncommon side effect — inflammation of the kidney can occur on checkpoint inhibitor treatment. Routine bloods usually detect it before symptoms appear, and the oncology team manages it, commonly with steroids.
• What to report between cycles — a clear drop in how much urine you are passing, new swelling in the ankles or legs, or feeling unusually drowsy and unwell. Tell the treating team rather than waiting for the next appointment.

• The closest comparison sits one organ away and works the opposite way round — a fixed course given after surgery, when nothing is visible on scans. Adjuvant Immunotherapy After Kidney Cancer Surgery sets out how that decision is made.
• Because maintenance runs open-ended, knowing which symptoms need reporting matters more than in a fixed six-cycle course. Urinary Symptoms During Immunotherapy: What Matters separates the ones to watch from the ones to call about.
• Kidney function is often already reduced by the time maintenance starts, after platinum chemotherapy or surgery. Immunotherapy on Dialysis or With Reduced Kidney Function covers what is possible when it is.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Not sure whether the scan after chemotherapy leaves maintenance open? Book a free consultation and a medical oncologist will read the reports with you.